Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
about
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationVaccines in development against West Nile virusNuclear reprogramming with a non-integrating human RNA virus.Development of replication-competent viral vectors for HIV vaccine delivery.Measles Virus Defective Interfering RNAs Are Generated Frequently and Early in the Absence of C Protein and Can Be Destabilized by Adenosine Deaminase Acting on RNA-1-Like Hypermutations.Sensitive detection of measles virus infection in the blood and tissues of humanized mouse by one-step quantitative RT-PCRMeasles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.RNA-based viral vectors.Vaccine platform recombinant measles virus.Multivalent and Multipathogen Viral Vector Vaccines.Chikungunya Virus Vaccines: Viral Vector-Based Approaches.Development of Recombinant Measles Virus-Based Vaccines.Measles Vaccine.
P2860
Q26700080-103D2D80-5817-4E0E-9404-96F9592C72F5Q26999702-84E84231-9D83-4447-86F9-BF96A9CE10C5Q30645806-B9E4E6EE-88F0-46C9-A25A-B03CD6A20999Q33694226-288DA43B-778C-43A5-8DD6-EB0262BBEE6FQ35861183-80D95417-B594-4F71-B776-C57013A8DD23Q37226470-4B99D3DE-C2C8-4CC8-8851-1AE5575FB330Q37520259-C26922D3-730D-4654-865A-D306C3B50CC6Q38266413-7A2F5601-D5E7-4BDC-865E-EEC284080691Q38657271-44E73D1E-ECAF-4669-9C8E-D9AAEC9FB49BQ38830323-8C9AF2C0-C0C6-4F2F-971E-268B347D5D00Q39128566-E3904CD2-2E6F-45E1-BD7D-77EFF4A94F7BQ40259612-267E024B-F680-47CE-9B92-1F1C7528D61EQ46300761-A0E012BD-730B-44D2-9056-607A0D6B5E68
P2860
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@ast
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@en
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@nl
type
label
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@ast
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@en
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@nl
prefLabel
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@ast
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@en
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@nl
P2093
P2860
P50
P1433
P1476
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
@en
P2093
Clarisse Lorin
Edward Mee
Gerald Voss
Joanna Hall
Marguerite Koutsoukos
Michèle Février
Nicola Rose
P2860
P304
P356
10.1371/JOURNAL.PONE.0050397
P407
P577
2012-11-30T00:00:00Z